This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and statements about the Company`s intentions, beliefs or expectations and that, by words such as “anticipate”, “believe”, “may continue”, “could”, “appreciate”, “expect”, “intention”, “likely”, “could”, “could”, “target”, “ongoing”, “plan”, “buddy nziell”, “predict”, “prognostic”, “aim”, “be”, “become”, or the negative or plural of these words or other similar expressions or variations, although not all forward-looking statements contain these identity words. In this press release, forward-looking statements include, but are not limited to, statements about Roivant Sciences and Sumitomo Dainippon Pharma`s plans for the alliance, including the date of completion of the final agreement, the date of conclusion of the alliance and the management of Urovant after closing; the company`s plans and strategies for the development and commercialization of innovative therapies for the treatment of urological diseases; the company`s expectations regarding its expected NDA application for Vibegron for OAB; the company`s expectations regarding its study of Vibegron in men with OAB and BPH and its study of Vibegron in patients with IBS-related abdominal pain; and the company`s expectations for its Phase 2a study for URO-902. “I am pleased to inform you that we have reached an agreement on the strategic alliance with Roivant, one of the strategic investments we are making to address our challenges in the 2022 medium-term business plan,” said Hiroshi Nomura, Deputy Director, President and Chief Executive Officer of Sumitomo Dainippon Pharma. “This strategic alliance allows us not only to acquire potential blockbusters and innovative healthcare technology platforms developed by Roivant, but also to deepen our relationship with Roivant, a company with an innovative business model and an underlying culture. We believe this relationship will contribute significantly to achieving a “global special player” position that we are aiming for by 2033. A formal agreement is being worked out and the final agreement is expected to be reached at the end of October. The reason they are announcing the deal now is to abide by the rules applicable to publicly traded companies in Japan. Sumitomo Dainippon Pharma Co., Ltd., headquartered in Osaka, Japan; Representative Director, Chairman and Chief Executive Officer: Hiroshi Nomura) announced today that it has reached a final agreement on a strategic alliance with Roivant Sciences Ltd (headquarters: London and Basel); Founder and CEO: Vivek Ramaswamy). As part of this strategic alliance, Sumitomo Dainippon Pharma of Roivant will acquire its stakes in five companies (Myovant, Urovant, Enzyvant, Altavant and Spirovant), options to acquire its stakes in six other companies, more than 10% of Roivant`s shares and selected healthcare technology platforms. . . .